Goldman Sachs
IBER

Goldman Sachs’s Ibere Pharmaceuticals IBER Stock Holding History

Goldman Sachs’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,995
Closed -$515K – 6431
2022
Q4 		$515K Hold
50,995
– – ﹤0.01% 4846
2022
Q3 		$505K Sell
50,995
-5,000
-9% -$49.3K ﹤0.01% 4963
2022
Q2 		$549K Hold
55,995
– – ﹤0.01% 5016
2022
Q1 		$549K Hold
55,995
– – ﹤0.01% 5257
2021
Q4 		$542K Hold
55,995
– – ﹤0.01% 5319
2021
Q3 		$543K Buy
55,995
+1,233
+2% +$11.9K ﹤0.01% 5145
2021
Q2 		$530K Buy
+54,762
New +$533K ﹤0.01% 5173

Goldman Sachs's IBER Position: Q1 2023 in Review

Goldman Sachs sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 50,995 shares — an estimated $515K sold.

Goldman Sachs first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $549K in Q2 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

  • Goldman Sachs reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 50,995 Ibere Pharmaceuticals shares in Q1 2023, an estimated $515K.
  • Goldman Sachs first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Goldman Sachs's Ibere Pharmaceuticals position peaked at $549K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.